GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
Federal court dockets show more than 4,000 pending Ozempic and GLP-1 lawsuits, reflecting a massive expansion of legal actions against manufacturers. Filings now encompass hundreds of vision loss claims and separate complaints regarding stomach injuries like gastroparesis and necrotizing pancreatitis. Legal scrutiny broadens as firms evaluate new product risks and oral weight-loss alternatives.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Federal court dockets contained 4,025 stomach-injury cases and 247 vision-loss cases related to Ozempic and GLP-1 drugs as of October 1, 2026.
- ✓ Legal claims involving GLP-1 medications target manufacturers over severe side effects, including vision loss and gastrointestinal complications.
What changed
Federal court dockets recorded 4,025 stomach-injury cases and 247 vision-loss cases pending as of October 1, 2026.
Live updates
-
GLP-1 Litigation Surges to Over 4,000 Federal Cases
Federal court dockets show more than 4,000 pending Ozempic and GLP-1 lawsuits, reflecting a massive expansion of legal actions against manufacturers. Filings now encompass hundreds of vision loss claims and separate complaints regarding stomach injuries like gastroparesis and necrotizing pancreatitis. Legal scrutiny broadens as firms evaluate new product risks and oral weight-loss alternatives.
Why it matters
The litigation centers on whether pharmaceutical companies adequately warned patients about severe complications linked to blockbuster diabetes and weight-loss treatments. As scientific studies probe links between semaglutide and ocular conditions such as NAION, plaintiffs are pressing courts for accountability regarding permanent impairments.
What is confirmed
- Federal court dockets contained 4,025 stomach-injury cases and 247 vision-loss cases related to Ozempic and GLP-1 drugs as of October 1, 2026.
- Legal claims involving GLP-1 medications target manufacturers over severe side effects, including vision loss and gastrointestinal complications.
Still unconfirmed
- Legal firms are evaluating potential claims regarding Foundayo due to suspected side effects.
- Novo Nordisk faces lawsuits from patients using the Wegovy pill who suffered complications.
What to watch next
- Progression of the 4,025 pending stomach-injury cases and 247 vision-loss cases in federal court.
- Updates on FTC legal actions involving Hims and Hers.
- Further findings linking semaglutide use to NAION and other severe eye problems.
confidence 100%Sources used for this update (6)
- www.robertkinglawfirm.com — Ozempic Blindness Lawsuit [2026 Update] - King Law
- glp1newshour.substack.com — Starving Brains, Vision Loss Lawsuits and Lilly at Vogue
- www.glp1picks.com — Ozempic & GLP-1 Lawsuit Tracker 2026: 4,025 Cases Pending
- masstortinfo.com — Ozempic Lawsuit - Best Expert Guide (2026)
- www.hercasematters.com — Saxenda Lawsuit | Side Effects, Vision Loss, & Updates
- www.motleyrice.com — Ozempic Pancreatitis: Symptoms, Risks & 2026 Medical Updates
-
GLP-1 Litigation Expands to Weight-Loss Pills and Vision Loss Claims
Legal actions against GLP-1 manufacturers are expanding to include oral weight-loss pills and specific claims of permanent vision loss. A 63-year-old diabetic patient is suing over becoming legally blind after using Ozempic. Additionally, Novo Nordisk faces lawsuits from patients using the Wegovy pill who suffered complications. Legal firms are also evaluating potential claims regarding Foundayo, another GLP-1 pill with suspected similar side effects. These developments broaden the scope of existing multidistrict litigation involving severe medical risks associated with the drug class.
Why it matters
GLP-1 medications are used for diabetes and weight management but are linked to severe digestive and neurological injuries. Current litigation, including MDL 3094, focuses on whether manufacturers provided adequate warnings about these risks. The shift toward pill-form medications introduces new variables in patient safety and liability.
Still unconfirmed
- A 63-year-old diabetic claims he became legally blind after starting Ozempic.
- Patients are suing Novo Nordisk for complications resulting from the Wegovy pill.
- Foundayo may have side effects similar to other GLP-1 drugs.
What to watch next
- Court rulings on the admissibility of vision loss as a side effect of Ozempic.
- Formal filing of mass tort actions specifically targeting Foundayo.
- Novo Nordisk's legal response to the Wegovy pill complications claims.
confidence 70%Sources used for this update (3)
- www.the-express.com — Ozempic user sues company after 'losing vision after shower ...
- www.robertkinglawfirm.com — Wegovy Pill Lawsuit [2026 Update] – Severe Risks & Legal Claims
- www.robertkinglawfirm.com — Foundayo Lawsuit [2026 Update] – Severe Side Effects ...
-
GLP-1 Weight-Loss Drug Lawsuits Expand Over Severe Medical Risks
Thousands of plaintiffs are suing the manufacturers of popular GLP-1 weight-loss drugs over allegations that companies failed to adequately warn users about severe medical risks. The legal actions center on serious conditions including blindness, bowel injuries, neurological damage, and digestive complications such as gastroparesis. Litigation is currently organized within multidistrict litigations, specifically including MDL 3094. Legal proceedings and scientific evaluations continue to face challenges as parties assess complex medical evidence and specific injury requirements.
Why it matters
The expansion of federal litigation highlights growing safety concerns regarding widely used semaglutide medications. Plaintiffs claim they were left in the dark about catastrophic side effects, prompting coordinated legal actions across the country. Meanwhile, regulatory bodies like the FDA are evaluating potential risks such as NAION vision loss.
What is confirmed
- Thousands of lawsuits accuse the makers of popular GLP-1 weight-loss drugs of failing to warn patients about risks including blindness, bowel injuries and neurological damage.
- Federal litigation involving popular GLP-1 medications expands as patients file lawsuits against manufacturers over severe conditions like gastroparesis and vision loss.
Still unconfirmed
- Ozempic gastroparesis claims require specific medical tests that could affect the outcome of GLP-1 lawsuits.
What to watch next
- Developments in MDL 3094 and qualification criteria for claims
- FDA decisions regarding regulatory measures for NAION risks
- Rulings on medical test requirements for gastrointestinal injury claims
confidence 100%Sources used for this update (4)
- www.centraloregondaily.com — 'My colon blew up': lawsuits mount over GLP-1 weight-loss drugs
- lawfold.com — Ozempic Lawsuit Morgan & Morgan (Updated October 2026)
- www.sokolovelaw.com — NAION Ozempic Lawsuit | GLP-1 NAION Risks 2026 - Sokolove Law
- www.legalexaminer.com — Could a Medical Test Affect Ozempic Lawsuits? GLP-1 ...
-
GLP-1 Drug Makers Face Mass Litigation Over Vision and Stomach Risks
Federal litigation involving popular GLP-1 medications expands as patients file lawsuits against manufacturers over severe conditions like gastroparesis and vision loss. Plaintiffs claim companies failed to adequately warn users about risks including NAION vision loss and digestive complications. Legal actions encompass thousands of claims currently grouped in multidistrict litigations. Meanwhile, the FDA is evaluating potential NAION risks to determine if regulatory measures are necessary. Scant data regarding serious adverse effects continues to complicate both legal and scientific assessments of how frequently these injuries occur.
Why it matters
The mounting litigation centers on widely used diabetes and weight loss treatments such as Ozempic, Wegovy, and Mounjaro. Plaintiffs allege that inadequate warnings from manufacturers left them unprepared for life-altering medical issues. These legal proceedings follow expert hearings held in September 2026 as the courts weigh scientific evidence.
What is confirmed
- Lawsuits are targeting makers of Ozempic, Wegovy, and Mounjaro over gastroparesis and vision loss side effects.
- The FDA is assessing possible NAION risks to decide if regulatory action is needed.
- Frank Campbell Jr. filed a lawsuit against Eli Lilly and Co. in Indiana alleging debilitating nausea, vomiting, and abdominal pain from gastroparesis after taking Mounjaro and Trulicity.
Still unconfirmed
- Todd Engel lost sight in one eye, continued injecting Ozempic, and subsequently lost vision in the other eye.
What to watch next
- A judicial ruling following the expert hearings held in September 2026.
- Decisions by the FDA regarding potential regulatory actions on NAION risks.
- Developments in the active multidistrict litigations covering vision loss and gastrointestinal injury claims.
confidence 90%Sources used for this update (8)
- www.aboutlawsuits.com — Ozempic Lawsuit, Wegovy Lawsuit and Mounjaro Lawsuit ...
- www.drugwatch.com — I Interviewed One of the Lead Attorneys in the Ozempic Vision ...
- www.motleyrice.com — Weight Loss Drug Lawsuits | Learn More About GLP-1 Lawsuits
- theclinicaltimes.com — Patients sue GLP-1 makers over alleged vision loss and other ...
- www.klcc.org — Ongoing lawsuits allege GLP-1s can cause serious harm ... - KLCC
- thedingodaily.com — Man Went Blind in Both Eyes on Ozempic. His Doctor Had Heard ...
- www.inkfreenews.com — Eli Lilly Sued Over Alleged Digestive Complications From GLP ...
- www.insideindianabusiness.com — Eli Lilly sued over stomach problems patient ties to Mounjaro ...
-
GLP-1 Lawsuits Expand as Massachusetts Man Claims Permanent Blindness
Federal litigation against GLP-1 drug makers now includes a Dedham, Massachusetts man who claims Ozempic caused him to go permanently blind. This case joins approximately 200 pending vision loss claims and over 3,900 gastrointestinal injury cases across two active multidistrict litigations. While plaintiffs allege drug manufacturers failed to warn users about risks such as NAION vision loss and gastroparesis, no settlements have been reached. Legal proceedings are currently awaiting a ruling following an expert hearing held in September 2026.
Why it matters
GLP-1 medications like Ozempic and Wegovy are used for weight loss and diabetes management. These lawsuits focus on severe side effects that plaintiffs claim were not adequately disclosed. The litigation targets major manufacturers including Novo Nordisk and Eli Lilly.
What is confirmed
- Two federal multidistrict litigations are active with roughly 3,928 GI injury cases and 200 vision loss cases.
- Serious risks associated with Ozempic include gastroparesis, pancreatitis, and NAION vision loss.
- Over 4,000 cases have been filed regarding gastroparesis and intestinal blockages.
- No settlement has been reached in the GLP-1 lawsuits as of October 2026.
Still unconfirmed
- A man from Dedham claims he became blind by June 1st after taking Ozempic.
What to watch next
- The court ruling following the September expert hearing
- Updates on potential compensation ranges for injury victims
confidence 90%Sources used for this update (13)
- www.drugwatch.com — Social Media Multidistrict Litigation 3047 Updates & Analysis
- www.yahoo.com — Mass. man joins lawsuit claiming Ozempic made him go blind
- nypost.com — Dad says he went permanently blind — in lawsuit against ...
- www.drugwatch.com — Ozempic Lawsuit: September 2026 Blindness and Gastroparesis ...
- www.drugwatch.com — Ozempic Side Effects: Common, Serious Risks & FDA Warnings
- www.yahoo.com — Experimental weight-loss shot helps patients keep weight off with fewer injections
- mdlupdate.com — Ozempic & Wegovy Lawsuit: Gastroparesis Claims | MDL-3094 ...
- lawcompensate.com — GLP-1 Lawsuit 2026: MDL Status, Case Counts, No Payout
- lawcounty.com — GLP-1 Lawsuit Settlements: Potential Compensation for Drug ...
- www.consumernotice.org — Ozempic Stomach Paralysis Lawsuit: Gastroparesis Claims
- lawsuittracker.org — Ozempic Lawsuit – October 2026 Update | Lawsuit Tracker
- www.motleyrice.com — Ozempic® Lawsuit | September 2026 Legal Updates - Motley Rice
-
GLP-1 lawsuits mount over vision loss claims
Hundreds of people are suing makers of GLP-1 drugs, such as Ozempic and Wegovy, alleging the medications caused vision loss. Plaintiffs describe life-changing effects, including permanent blindness. Lawsuits claim drug manufacturers failed to warn users of the risk. Experts say claims will be hard to prove. The legal landscape is evolving, with multiple multidistrict litigations underway.
Why it matters
GLP-1 receptor agonists are popular weight-loss and diabetes medications. Recent reports of vision loss linked to these drugs have led to a surge in lawsuits. Regulatory bodies are investigating the rare eye risk. The outcome of these cases could impact the pharmaceutical industry and public perception of GLP-1 drugs.
What is confirmed
- At least 12 cases of permanent blindness have been reported in users of GLP-1 drugs.
- Hundreds of people are suing GLP-1 drugmakers over vision loss claims.
- The MDL 3094 has 4022 cases, and MDL 3163 has 216 cases.
- A Georgia nurse practitioner claims she woke up with vision loss in one eye after taking a GLP-1 drug.
- A patient's attorney describes life-changing effects from taking a GLP-1 drug, including permanent blindness.
Still unconfirmed
- Expert says GLP-1 vision loss claims will be hard to prove.
What to watch next
- The outcome of the MDL 3163 vision-loss case hearing
- Any regulatory updates on GLP-1 drug safety
- The number of lawsuits filed in MDL 3094 and 3163
confidence 90%Sources used for this update (15)
- USA Today — Are GLP-1s causing blindness? What we know about rare cases
- ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
- The Boston Globe — Could GLP-1s be linked to a rare type of vision loss? Here’s what to know.
- Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
- NewsNation — GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
- MassLive.com — GLP-1 companies face flurry of lawsuits after consumers say drugs caused vision loss
- voz.us — 12 cases of permanent blindness: Internal medicine doctor explains risks behind popular GLP-1 drugs on 'Voz News'
- NewsNation — ‘Dark, scary’: GLP-1 user who lost vision says he received no warning
- KOAT — Expert says GLP-1 vision loss claims will be 'hard to prove'
- www.yahoo.com — Hundreds Sue GLP-1 Drugmakers Over Vision Loss as Regulators Weigh Rare Eye Risk
- www.yahoo.com — GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
- www.yahoo.com — Novo’s next-gen weight-loss drug outperforms Zepbound in new trial
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community